Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CStone Approved to Market Precision Medicine Drug for AML Patients

publication date: Feb 11, 2022

Suzhou CStone Pharma (HK: 2616) was approved to market Tibsovo® (ivosidenib tablets) in China for adult patients with relapsed/refractory acute myeloid leukemia who have a susceptible IDH1 mutation. About 75 thousand new cases of leukemia are diagnosed each year in China, 59% of whom are AML patients including up to 10% with IDH1 mutations. Tibsovo is an oral targeted IDH1 inhibitor that offers a new precision medicine for the condition. In a China bridging study, Tibsovo® produced a complete response in 37% of these patients. The approval is CStone's fourth in China. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China